Where does stocks-llm's data on ZYME come from?

Fundamentals and prices come from Finnhub, as of 2026-07-10; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.

← stocks-llm Find companies like ZYME →

ZYMEWORKS INC (ZYME)

Health Care · Antibody therapeutics and bispecific antibody-drug conjugate development · NASDAQ

A biotech company pioneering multispecific antibodies and ADCs for cancer and autoimmune disease, monetizing through a partnership-driven royalty aggregation model while advancing an internal pipeline.

View SEC filings Website Yahoo Finance Find companies like ZYME → Ask about ZYME →

What ZYMEWORKS INC does

Zymeworks is a global biotechnology company that develops novel biotherapeutics targeting cancer, inflammation, and autoimmune disease through proprietary multispecific antibody therapeutics (MSATs) and antibody-drug conjugate (ADC) platforms. The company executes an asset and royalty aggregation strategy, managing a portfolio of licensed healthcare assets and product candidates while pursuing partnerships to generate milestone and royalty cash flows. Its first approved product, zanidatamab (Ziihera), a bispecific antibody for HER2-positive biliary tract cancer, is commercialized through strategic partners BeOne Medicines and Jazz Pharmaceuticals, providing near-term milestone and royalty revenues.

Themes: ["Bispecific antibodies / multispecific therapeutics","Oncology / HER2-positive cancer","Antibody-drug conjugates (ADCs)","Inflammation and autoimmune disease","Royalty aggregation / partnership-based monetization","Early-stage drug development"]

Fundamentals

Price$27.07 as of 2026-07-09 close
Market cap$2.0B as of 2026-07-10
1-year return+99.5% as of 2026-07-09 close
Net margin-126.3% as of 2026-07-10
ROE-37.8% as of 2026-07-10
Debt / equity0.00 as of 2026-07-10
Revenue growth (YoY)+3.3% as of 2026-07-10
Revenue CAGR (3y)-36.4% SEC XBRL
Beta1.14 as of 2026-07-10

Ask why ZYME looks like this →

Key risks (from latest filing)

["Regulatory and clinical development uncertainty: the company's business depends on regulatory approval and successful commercialization of product candidates, with no guarantee of timing or success; reliance on strategic partners for development and commercialization creates dependency on third-party execution and decisions","Cash burn and funding dependency: the company is unprofitable with an accumulated deficit of $1.07 billion and negative net margins of -126%, requiring continued capital from public markets and milestone/royalty revenues to fund operations","Partnership execution risk: the company's near-term cash generation depends on BeOne and Jazz successfully commercializing zanidatamab and achieving clinical and regulatory milestones for other partnered programs"]

See ZYME's biggest risks from its latest 10-Q →

Competitors & peers

Not quite? Describe exactly what you want →

Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-07-09.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.